UroGen Pharma (URGN) Profit After Tax (QoQ) (2018 - 2026)
UroGen Pharma (URGN) Profit After Tax (QoQ) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | UroGen Pharma | 2.05 Bn | 1.91 Bn | 46.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.71% |
| Dec 31, 2025 | 20.79% |
| Sep 30, 2025 | 33.27% |
| Jun 30, 2025 | -118,823.81% |
| Mar 31, 2025 | 99.89% |
| Dec 31, 2024 | -14,149.44% |
| Sep 30, 2024 | 4,350.00% |
| Jun 30, 2024 | 100.02% |
| Mar 31, 2024 | -24.29% |
| Dec 31, 2023 | -18.91% |
| Sep 30, 2023 | 9.35% |
| Jun 30, 2023 | 20.11% |
| Mar 31, 2023 | -63,043.75% |
| Dec 31, 2022 | 100.19% |
| Sep 30, 2022 | 2.85% |
| Jun 30, 2022 | 5.99% |
| Mar 31, 2022 | 74.32% |
| Dec 31, 2021 | -265.44% |
| Sep 30, 2021 | -14.94% |
| Jun 30, 2021 | -20,462.50% |